Consider IXINITY® for your active hemophilia B patients.

Peak factor levels when they need them.

Active people with hemophilia B who want effective bleed prevention and control and peak factor levels when they need them may benefit from treatment with IXINITY.1

Chris Kelly: College student and avid outdoorsman

Age: 20

Weight: 180 lb

Severity: Severe hemophilia B

Previous therapy: Plasma-derived product

Current therapy: IXINITY

Treatment regimen: Before hiking and on-demand


  • Developed an inhibitor as a child and switched to a plasma-derived product. Did not go back to a recombinant because of the plasma's low-dose infusion.


  • IXINITY offers him a recombinant option with 0.98 IU/dL mean incremental recovery.1*

Description is not of an actual patient.

Jacob Cook: Devoted husband and active cyclist

Age: 31

Weight: 192 lb

Severity: Moderate hemophilia B

Previous therapy: Recombinant factor IX product

Current therapy: IXINITY

Treatment regimen: Infuses 2x/week based on his cycling schedule


  • Infuses before a big ride to reach peak factor level when his physical activity is greatest.


  • IXINITY fits Jacob's active lifestyle by providing peak factor levels when he needs them.1*

Description is not of an actual patient.

Scott Wright: Scholarship swimmer

Age: 18

Weight: 173 lb

Severity: Moderate hemophilia B

Previous therapy: Recombinant factor IX product

Current therapy: IXINITY

Treatment regimen: Infuses before major training sessions


  • Will be independent at college and wants peak factor levels when he needs them and easy factor IX storage.


  • IXINITY works for Scott because of its 24-hour half-life and room-temperature storage.1*

Description is not of an actual patient.

Explore more about IXINITY



INDICATIONS AND USAGE: IXINITY® [Coagulation Factor IX (Recombinant)] Lyophilized Powder for Solution for Intravenous Injection is a coagulation factor IX (recombinant) indicated in adults and children ≥12 years of age with hemophilia B for control and prevention of bleeding episodes, and for perioperative management.

IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

CONTRAINDICATIONS: IXINITY is contraindicated in patients who have known hypersensitivity to IXINITY or its excipients, including hamster protein.

WARNINGS AND PRECAUTIONS: Hypersensitivity reactions, including anaphylaxis, may occur following IXINITY administration. Discontinue use of IXINITY if hypersensitivity symptoms occur, and initiate appropriate treatment. Regularly evaluate patients for the development of factor IX inhibitors by appropriate clinical observations and laboratory tests. If expected factor IX activity plasma levels are not attained, or, if bleeding is not controlled as expected with a certain dose, perform an assay that measures factor IX inhibitor concentration. An association between the occurrence of a factor IX inhibitor and allergic reactions has been reported. Individuals with factor IX inhibitors may be at increased risk of severe hypersensitivity reactions or anaphylaxis if re-challenged.

Nephrotic syndrome may occur with IXINITY. Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions.

Thromboembolism may occur when using IXINITY (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis).

Patients may develop hypersensitivity to hamster (CHO) protein as IXINITY contains trace amounts.

The most common adverse drug reaction observed in >2% of patients in clinical trials was headache.

Please see full Prescribing Information.

Medical Affairs e-mail:

To report an adverse event, please call 1-844-859-6675.

*The efficacy (n=68) and safety (n=77) of IXINITY has been evaluated in a prospective, open-label, uncontrolled, multicenter trial in which previously treated patients (PTPs) between 7 and 64 years of age received IXINITY in either a routine treatment or on-demand regimen.1

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Seattle, WA: Aptevo BioTherapeutics LLC; December 2018.